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Abstract
The aim of this chapter is to describe targets for analgesic drugs, including currently
available target sites and possible future target sites for pain and information regarding
analgesia for complete understanding of pain originating mechanism, pathways and
related theories to recognize. This chapter fully describes methods for determination of
analgesic effects of synthetic and natural substances by inducing pain in different
models and methods of pain induction.
Keywords: pain, analgesics, targets, sources
1. Introduction
Pain is the measure of a cautious response against organ damage or unevenness in its capaci-
ties against conceivably unsafe stimulation. The rising pathway of pain incorporates the
contralateral spinothalamic tract, lateral pons, mid brain to thalamus and at last, through the
somatosensory cortex of the cerebrum that defines the zones, force and profundity of pain [1].
Pain is the most widely recognized experience reported by patients, and patient tension is a
type of caution sign. It is an exotic and perceptual sensation, which causes enduring and
enthusiastic condition of dangers associated with tension. Pain has numerous structures. It
cautions against harm to the body, which is critical for maintaining a strategic distance from
wounds and thus for survival. Pain not brought about by intense wounds can be insalubrious
for the patient, or it can adjust a man’s life, decrease the personal satisfaction and furthermore
affect the patient’s family. ‘Pain’ for the patient means malady and enduring, for the specialist,
it is a side effect and for the physiologist, it is a sort of feeling that has its own particular
anatomical and physiological framework which starts with the receptors and winds up in the
cerebrum cortex. Feeling is a physical impression that can be affirmed by electrophysiological
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techniques, however, by and by, it is just a subjective sensation. Its force and quality go under
different inside and outer elements; in this way, the same boost can be experienced distinc-
tively in various circumstances and substantial and psychiatric conditions. The method for
accepting pain is extremely individual and differs every once in a while in the same person.
The force of pain is hard to quantify, and an individual’s impression of nuisance relies upon the
individual’s enthusiastic state, circumstances under which the pain was obtained and whether
it is seen as an undermining signal [2–4]. Before we understand that something harms, there
are various physiological procedures in our body. Painful stimuli must be passed rapidly, in
(milli) seconds. Intense pain cautions about looming or following risk while continual pain
causes the burdened part of the body, for example, an immobilized and unused appendage,
expanding the chance for healing. A solitary and sharp stimulus to pain can vanish and most
likely not leave a track. Pain progression can be supported and inhibited by the adaptive
changes in the central nervous system due to the repeated stimuli. Sense of pain is modified
by the synthesis and activation of many receptor systems along with synthesis of numerous
compounds in the brain and spinal cord. In this complicated process, glial cells perform a
significant role in the preservation of the pain, even after the pain stimulus is disappeared [5].
In the peripheral and central nervous system, pain can also be generated without receptors. This
sort of pain is always a pathological pain which ascends due to injury to the nervous system, and
it has an altered nature from physiological pain and clinical presentation. Therefore, it is impor-
tant to distinguish receptor pain—nociceptive, physiological pain from non-receptor pain—
pathological, central and peripheral. In Table 1, different types of pain are defined.
Utilization of an intense harmful stimulus to ordinary tissue inspires intense physiological
nociceptive pain. It shields tissue from being (further) harmed in light of the fact that with-
drawal reflexes are typically inspired. Pathophysiological nociceptive pain happens when the
tissue is excited or harmed. It might show up as unconstrained (pain without any deliberate
incitement) or as hyperalgesia and/or allodynia. Hyperalgesia is a compelling pain force felt
upon harmful incitement, and allodynia is the impression of discomfort inspired by stimuli
that are ordinarily underneath pain edge. In non-neuropathic pain, a few creators incorporate
the bringing down of the pain limit in the term hyperalgesia. While nociceptive pain is inspired
by incitement of the tactile endings in the tissue, neuropathic pain results from harm or
sickness of neurons in the peripheral or central nervous system. It does not essentially signal
Allodynia Pain on account of a stimulation that does not customarily induce pain, e.g. pain brought on by a T-shirt
patients with postherpetic neuralgia
Dysesthesia An unpalatable anomalous sensation, whether unconstrained or evoked while paresthesia is not
upsetting, e.g. in patients with diabetic polyneuropathy or lack of vitamin B1
Hyperalgesia An expanded reaction to a jolt that is typically painful
Hyperesthesia Expanded affectability to incitement, barring the exceptional senses, e.g. expanded cutaneous sensibility
to warm sensation without agony/pain
Source: International Association for the Study of Pain.
Table 1. Types of pain.
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noxious tissue stimulation and often feels abnormal. Its character is regularly smouldering or
electrical, and it can be relentless or happen in short parts (e.g. trigeminal neuralgia), it might
be consolidated with hyperalgesia and allodynia. Amid allodynia notwithstanding touching
the skin can bring about serious pain. Reasons for neuropathic pain are various, including
harm to central neurons (e.g. in the thalamus), axotomy, nerve or plexus harm, metabolic
ailments such as diabetes mellitus or herpes zoster [6].
1.1. The nociceptive system
Nociception is the encoding and preparing of toxic boosts in the sensory system that can be
measured with electrophysiological procedures. Neurons involved in nociception structure the
nociceptive framework. Harmful boosts enact essential nociceptive neurons with ‘free nerve
endings’ (Aδ and C strands, nociceptors) in the peripheral nerve. A large portion of the
nociceptors reacts to toxic mechanical (e.g. crushing the tissue), warm (warmth or frosty) and
substance jolts and in this manner is polymodal [7].
Nociceptors can likewise apply efferent capacities in the tissue by discharging neuropeptides
(substance P (SP), calcitonin gene related peptide (CGRP)) from their tactile endings. Along
these lines, they impel vasodilatation, plasma extravasation, attraction of macrophages or
degranulation of mast cells and so on. This aggravation is called neurogenic inflammation [8].
Nociceptors and second-order neurons in the grey matter of the dorsal horn make synapses
and nociceptors protrude towards spinal cord. A conscious pain response is produced due to
the ascending axons of the second-order neurons and projection of brain stem or
thalamocortical system upon noxious stimulation. Nociceptive motor reflexes include many
spinal cord neurons that involve more unpredictable motor behaviour, such as hindrance in
movements and generation of autonomic reflexes. The spinal nociceptive processing is
reduced by descending tracts. These tracts are formed by pathways that originate from brain
stem nuclei (in particular the periaqueductal grey, the rostral ventromedial medulla) and
descend in the dorsolateral funiculus of the spinal cord. An intrinsic anti-nociceptive system
involves this type of descending inhibition [9].
1.1.1. The peripheral pain pathway: primary afferent nociceptors
In skin, muscle and joint, numerous Aδ and C fibres thresholds have elevated for mechanical
stimuli, along these lines going about as particular nociceptors that recognize possibly or really
harming mechanical boosts. Mechano-receptors are fast-conducting Aβ afferents with corpuscu-
lar endings that react overwhelmingly to harmless mechanical boosts. An extent of Aδ and C
strands results in warmth or frosty receptors encoding harmless warm and cold jolts yet not toxic
warmth and cold. Notwithstanding polymodal nociceptors, joint, skin and instinctive nerves
contain Aδ and C fibres that were named silent or initially mechano-insensitive nociceptors.
These neurons are not enacted by harmful mechanical and warm boosts in typical tissue. Be that
as it may, they are sharpened amid aggravation and after that begin to react to mechanical and
warm jolts [10, 11]. This type of neurons produces enduring reaction to algogenic chemicals and
also involved in intervening neurogenic inflammation in human beings [12]. They assume a
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noteworthy part in starting central sensitization [13]. These neurons have unmistakable axonal
biophysical qualities isolating them from polymodal nociceptors [11].
1.1.1.1. Peripheral neuronal mechanisms of neuropathic pain
When nociceptive field is stimulated, action potentials are generated in the sensory endings of
healthy sensory nerve fibres. Pathological ectopic discharges are expressed in damaged nerve
fibres. At the site of nerve damage or in the cell body of DRG, action potentials are generated.
The released designs shift from recurrent terminating to irregular blasts [14, 15].
Ectopic releases happen in Aδ and C fibres and in thick myelinated Aβ fibres. In this manner,
after nerve damages both low-threshold Aβ and in addition high-threshold Aδ and C fibres
might be included in the era of torment. The procedures of central sensitization have been
experienced by Aβ fibres that may inspire misrepresented reactions in spinal cord neurons. It
was recommended that pain is not created by the impaired nerve parts themselves but instead
by nerve fibres in the region of harmed nerve elements. After an exploratory sore in the L5
dorsal root, unconstrained activity potential releases were seen in C fibres in the uninjured L4
dorsal root. These filaments might be influenced by the procedure of a Wallerian degenera-
tion [16].
1.1.2. Central pain pathways
1.1.2.1. The spinothalamic pathway
Dorsal root ganglia are a door to spinal cord for the entrance of nerve fibres where these nerve
fibres impregnate around the spinal cord (dorsolateral tract of Lissauer) as 1–2 sliced parts and
interact with the nerve cells in Rexed lamina I (marginal zone) and lamina II (substantia
gelatinosa) then arrive the spinal grey matter. Substantia gelatinosa layer of the spinal cord is
for the innervation of C fibres and marginal zone is for the innervation of Aδ fibres. These
innervation of nerve cells is proceeded in the nucleus proprius (an area of spinal cord grey
matter involving Rexed layers IV, V and VI), which remains continue to spinal midline then
come up (in the anterolateral or ventrolateral part of the spinal white matter) through the
medulla and pons and finally reaches the thalamus particular zone.
In this way, pain information and normal thermal stimuli (<45C) are transmitted through
spinothalamic pathway. The thalamic pathway encountering anomaly represents as a cradle
of pain; this can be seen in patients with central pain or thalamic pain after stroke in the region
of paralysis. In Figure 1, bradykinins, Kþ and prostaglandins are released by tissue injury thus
stimulates nociceptors and subsequent release of substance P and histamine produce vasodi-
lation and swelling.
1.1.2.2. The trigeminal pathway
Trigeminal ganglion and cranial nuclei VII, IX and X are the sites for the nerve cells to recognize
the harmful stimuli through the nerve fibres where nerve fibres cross the threshold to the
brainstem as well as medulla. Across the neural midline, these nerve fibres ascend to the
contralateral side of the thalamic nerve cell. Trigeminal neuralgia is defined as the spontaneous
firing of trigeminal nerve ganglion (In the positive results of Janetta’s trigeminal decompression
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surgery, cerebellar artery and local trigeminal nerve damage by mechanical lesion is thought to
be cause).
The range of the thalamus that gets the pain data from the spinal cord and trigeminal nuclei is
additionally the territory that gets data about normal sensory stimuli, for example, touch and
pressure. From this territory, nerve fibres are sent to the surface layer of the cerebrum (cortical
regions that arrangement with sensory data).
In this way, evidence on the area and the intensity of the pain can be handled to wind up a
‘confined painful feeling’ by having both the nociceptive and the normal somatic sensory
information focalize on the same cortical territory.
In certain situations, e.g., after limb amputations, cortical representation may change into two
types of painful (‘phantom pain’) and non-painful sensations (‘telescoping phenomena’) [18].
In Figure 2, the raphe nucleus provides serotoninergic (5-HT), and locus ceruleus provides
adrenergic modulation. Therefore, selective serotonin reuptake inhibitors (SSRIs) and tricyclic
antidepressants (e.g., amitriptyline) may exhibit analgesic properties.
1.1.3. Pain theories
1.1.3.1. Specificty theory
In this theory, Descartes suggested that harmful and non-harmful perceptions can be distin-
guished by the decoding of specific pain fibres [19].
Figure 1. Nociceptor stimulation by tissue damage and vasodilation and swelling by the release of histamine (modified
from Patel [17]).
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1.1.3.2. Intensity theory
Sydenham proposed that the peripheral stimulus acts as a signal whose intensity determines
which type of sensation should be percieved [20].
1.1.3.3. Gate control theory
Melzack and Wall recommended that second-order spinal neurons (Dorsal horn transmission
cell or wide dynamic range (WDR) neuron are stimulated by sensory fibers of divergent speci-
ficity that, unpredictably fire, subject to their degree of facilitation or inhibition. Inhibitory
substantia gelatinosa (SG) cells are stimulated by large sensory fibres because in dorsal horn
transmission cells are triggered by both large and small diameter afferents [21]. In the substantia
gelatinosa, neuron and integrated circuits regulate the opening and closing of ‘gate’ [22].
Direct suppression of transmission cells by SG cells close the gate. On the other hand, the SG
cells suppressive effect declines due to the amplified activity in small diameter fibres which
can also be increased by the peripheral nerve damage and cause the opening of gate and also
face decrease in inhibition of large fibres [23].
2. Target of pain: central and peripheral
2.1. Peripheral targets
At the peripheral terminal, pro-inflammatory mediators are released from themast and schwann
cells, macrophages and neutrophils which are resident and migrating cells, respectively, due to
the injury to cells and blood vessels in return of stimuli, for example, a tissue damage or
infection. Dorsal root ganglion (DRG) cells hold receptors for these mediators, which upon
activation initiates a cascade of event from the intracellular kinases. In turn, receptor
Figure 2. Serotoninergic (5-HT) and adernergic modulation by the raphe nucleus and locus ceruleus. PAG—periaqueductal
grey matter, part of endogenous opioid system (modified from Patel [17]).
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phosphorylation causes the terminal sensitization, amplified afferent movement and stimulation
at lower threshold.
2.2. Central targets
The spinal primary afferents due to cell insult, such as tissue injury, inflammation or nerve
injury activate the primary afferents and induce voltage gated calcium cannels (CaV) and
soluble N-ethylmaleimide-sensitive factor activating protein receptor (SNARE) Protein-depen-
dent release of neurotransmitters, growth factors and neuropeptides. The resident glial and
migrating cells (T cells, macrophages and neutrophils) in the spinal cord along with the
second-order neurons are activated by the release of these substances, which in turn release a
collection of pro-inflammatory and anti-inflammatory molecules to further act on the second-
order neurons activating several protein kinases responsible for the phosphorylation of several
membrane bound receptors, thus initiating and maintaining the hyperexcitable state of these
neurons, and further sending the nociceptive signals to higher brain centres. The second-order
neurons facilitate the excitability of dorsal horn projection neurons and scheme onto raphe-
spinal serotonergic neurons through the bulbospinal pathway which dismiss in dorsal horn
neurons [24]. In Table 2, central and peripheral pain targets are shown along with their source
of cell insult/stimuli and inflammatory mediators and receptors which are and may be the
future targets for pain alleviation.
2.3. Pain targets with molecular mechanisms of activation and sensitization of nociceptors
In Figure 3, Nociceptors direct ion channels for generation of transduction and action poten-
tial, and a large number of receptors for inflammatory and other mediators are either coupled
to ion channels or, more often, activate second messenger systems that influence ion channels.
2.3.1. Transient receptor protein (TRP) channels
The transient receptor protein subfamily V member 1 is an individual receptor from the TRP
(transient receptor protein) family. Other TRP individuals might be transducers of temperature
boosts in different extents [26]. Capsaicin, the compound in hot pepper, opened the ion
channel that grounds burning pain. Specifically, Ca2þ moves through this channel and depo-
larizes the cell. The TRPV1 receptor is opened by heat (>43C) thus measured one of the
transducers of noxious heat. In TRPV1 knock-out mice, the heat response is not eradicated
but the mice do not display thermal hyperalgesia throughout inflammation, presenting the
significance of TRPV1 for inflammatory hyperalgesia [27, 28]. Up-regulation of TRPV1 tran-
scription during inflammation explains longer lasting heat hypersensitivity. The TRPV2 recep-
tor in nociceptors is assumed to be a transducer for exciting heat (threshold >50C). TRPA1
could be the transducer molecule in nociceptors reacting to frosty. It is actuated by impactful
mixes, e.g. those present in cinnamon oil, mustard oil and ginger. By differentiation, TRPV3
and/or TRPV4 might be transduction molecules for harmless warmth in warm receptors and
TRPM8 may transduce chilly jolts in harmless cold receptors. Despite the fact that the putative
warmth transducer TRPV4 demonstrates some mechano-sensitivity, it is still in vague whether
TRPV4 is included in the transduction of mechanical stimuli [29–31].
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Type of targets Peripheral targets Central targets
Stimulus Tissue injury, inflammation or infection Tissue injury, inflammation or nerve damage
Source Local/resident cells Migrating
cells (Local/
DRG)
Resident
cells
Spinal neurons Migrating
cells
Endothelial cells Macrophages Astrocytes T cells
Keratinocytes Neutrophils Microglia Macrophages
Mast cells Bacteria Neutrophils
Schwann cells
Inflammatory
mediators and
receptors
DNA, RNA, HMGB1 TLRs Pro-
analgesics
Anti-analgesics
Chemokines Cytokines
CCL21 IFNy, IL-4, IL-10, IL-
14
CCL2 Lipid mediators
Cytokines Resolvins
TNF, IL-1β,
IL-6
Protectins
Growth
factors
Lipoxins
ATP Epoxy fatty acids
Epoxyeicosatrienoic
acids
FPS FPR1 Second-order neurons
Bradykinins, 5-HT, CGRP,
Prostaglandins, Lipoxygenases,
proteinases
GPCRs
Protein
kinases
Receptors
ATP Purinergic
Receptors
CaMK NK-1
NGF, BDNF TRK PKA NMDA
Chemokines (e.g. CCL2, CXCL1) Chemokines
Receptors
PKC AMPA-CP
Cytokines (e.g TNF, IL-1β) Cytokines
Receptors
MAPK mGluR1
sP NK1 mGluR5
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2.3.2. Voltage-gated sodium channels and acid sensing ion channels
Tetrodotoxin (TTX) hindered many voltage-gated Naþ channels and numerous small dorsal
root ganglion (DRG) cells direct TTX-resistant (R) Naþ channels, notwithstanding TTX-
sensitive (S) Naþ channels. Both TTX-S and TTX-R Naþ channels pay to the Naþ influx
during the action potential. Excitingly, inflammatory mediators pre-disposed TTX-R Naþ
currents. Nociceptors are sensitized by boosted prostaglandin E2 (PGE2). This raises the
likelihood that TTX-R Naþ channels likewise assume a part in the transduction procedure
of poisonous boosts. SNS/ knock-out mice (SNS is a TTX-R Naþ channel) show declared
mechanical hypoalgesia, however just little shortages in the reaction to thermal incite-
ments [32, 33]. Low pH values cause opening of acid sensing ion channels (ASICs) and are
Naþ channels. In general, ASIC family comprises of six subunits (1a, 1b, 2a, 2b, 3, and 4).
This is of interest because many inflammatory exudates exhibit a low pH. Protons straight-
forwardly initiate ASICs with ensuing generation of action potentials. The ASIC family
expressed in peripheral neurons is ASIC 1b and ASIC 3 subunits which possess a high degree
of selectivity in sensory neurons [34, 35].
Figure 3. Ion channels for transduction of thermal and mechanical stimuli and action potential generation and metabotropic
receptors subserving chemosensitivity involving sensory ending of nociceptor (modified from Schaible [25]).
Type of targets Peripheral targets Central targets
Hþ ASIC P2X
Lipids TRPV1 GABA-A
TRPA1 Glycine
5HT3R
Source: Yaksh et al. [24].
Table 2. Schematic representation of peripheral as well as central targets from the point of insult to cells, sources of cell
insult and inflammatory mediators and receptors for the current and future analgesics.
Analgesics: New Target and Sources
http://dx.doi.org/10.5772/67853
323
2.3.3. Receptors of inflammatory mediators (chemosensitivity of nociceptors)
The chemosensitivity of nociceptors permits inflammatory and trophic intermediaries to
follow up on these neurons. Inflammatory cells and non-neuronal tissue cells are their
cradles. In the activation and sensitization of neurons, two types of receptors either
ionotropic (the mediator opens an ion channel) or metabotropic (the mediator activates a
second messenger cascade that influences ion channels and other cell functions) are
encompassed. Numerous receptors are coupled to G proteins, which signal by means of
the generation of the second messenger cyclic adenosine monophosphate (cAMP), cyclic
guanosine monophosphate (cGMP), diacylglycerol and phospholipase C. The receptors are
having intrinsic protein tyrosine kinase domains that associate with cytosolic tyrosine
kinases and protein serine/threonine kinases [31, 36]. There are several functions of media-
tors, which may involve the direct activation of neurons (e.g. the bradykinin induces action
potentials by itself) and/or sensitization of neurons for mechanical, thermal and chemical
stimuli (e.g. bradykinin and prostaglandins increase the excitability of neurons so that
mechanical stimuli arouse action potentials at a lower threshold than under switch circum-
stances occur). PGE2, for example, activates G protein-coupled EP receptors that cause an
increase of cellular cAMP. This second ambassador actuates protein kinase A, and this
pathway impacts ion channels in the membrane, prompting an improved edginess of the
neuron with brought down limit and expanded action potential recurrence inspired amid
suprathreshold incitement. Bradykinin receptors are of awesome interest on the grounds
where bradykinin enacts various Aδ and C fibres and sharpens them for mechanical and
warm boosts [37]. Freund’s complete adjuvant induced mechanical hyperalgesia of the rat
knee joints and thermal hyperalgesia can be reversed by the bradykinin receptor antago-
nists. A few reports recommend that specifically bradykinin B1 receptors are up-controlled
in sensory neurons taking after tissue or nerve damage, and that B1 antagonist diminishes
hyperalgesia. Up-regulation of B2 receptors during inflammation also found by some
authors [38, 39].
2.3.4. Neuropeptide receptors and adrenergic receptors
Receptors for a few neuropeptides have been recognized in primary afferent neurons, includ-
ing receptors for the excitatory neuropeptides SP (neurokinin 1 receptors) and CGRP, and
receptors for inhibitory peptides, in particular for opioids, somatostatin and neuropeptide Y
(NPY) [40, 41].
3. Current strategies for pain control
The treatment of constant pain ought to be multi-directional. There are pharmacological
strategies for treatment, physical, rehabilitation, neuromodulation, psychological techniques
and now and again, surgical methods. It is critical to guarantee careful and exhaustive nurture
of the patient, and to elucidate and acquire acknowledgment of the picked strategy for treat-
ment from the patient.
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3.1. Pharmacotherapy
Pharmacotherapy should always be chosen independently be chosen exclusively, in light of the
fact that what helps one individual does not as a matter of course help another, and may even
be unsafe. The decision of medication ought to be founded on fitting finding and presently
utilized pain relieving treatment. It is critical to consider conceivable symptoms which hap-
pened amid the past utilization of the medications. It is additionally critical to consider
conceivable association of the proposed drug with different pharmaceuticals utilized by
patient for different illnesses. To get a viable pain control, a blend of medications with various
components of activity is utilized. They are additionally accessible as prepared details
containing a mix of two or more active ingredients. In Table 3, some nociceptive conditions
are described which can be managed by the drugs interfering neurotransmission.
3.1.1. Classification of Non-steroidal anti-inflammatory drugs
Currently used non-steroidal anti-inflammatory drugs with their mechanism of actions, indi-
cations, therapeutic advantages and disadvantages are listed in the Table 4.
3.2. Physical therapy and rehabilitation
A supporting technique is utilized as a part of the treatment of pain. The most well-known
strategies for physical treatment are thermotherapy (heat), cryotherapy (cool), laser treatment,
electrotherapy, manual methods, restorative concentrates and kinesiotherapy. These tech-
niques, utilized as a part of a fitting way, may enhance life and portability of a few patients.
3.3. Neuromodulation
Neuromodulating treatments are aimed at stimulating the pain systems. Currently, several
neuromodulation methods are used: percutaneous nerve electrostimulation (TENS), periph-
eral nerve stimulation, acupuncture and vibration. Neuromodulation supports pain treatment
Conditions Pain management
Inflammatory states NSAIDs, act on COX-1, COX-2 and opiate receptors
Nerve injury Antidepressants, MAO Inhibitors, e.g. Amitriptyline, Duloxetine,
Venlafaxine
Neuropathic pain Sodium channel blockers (Lidocaine, Carbamazepine)
Calcium channel blockers (Ziconotide, Gabapentin)
Increasing extracellular level of inhibitory transmitter (GABA), e.g.
Tigabin
Opioids (lesser extent)
Topical medication for cutaneous allodynia and
hyperalgesia
Lidocaine, Capsaicin
Source: Sinatra [42].
Table 3. Pain conditions and Current analgesics for pain management.
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NSAID Mechanism of action Therapeutic
advantages
Therapeutic
disadvantages
Indications
Salicylates
Aspirin Irreversibly inhibit
COX-1 and COX-2
Low cost; long history
of safety
Upper GI disturbances are
common
Fever, pain, anti-
inflammatory and anti-
platelet
Diflunisal No anti-pyretic effect
Acetic acids
Indomethacin Reversible inhibitors
of COX-1 and COX-2
Upper GI disturbances are
common
Anti-pyretic, analgesic,
anti-inflammatory
Very potent should be
used only after less toxic
agents have proven
ineffective
Sulindac Long half-life permit
once or twice daily
dosing
Same as indomethacin but
less sever
Fever, pain inflammation,
RA, ankylosing
spondylitis, osteoarthritis
of hip
Propionic acids
Ibuprofen Reversible inhibitors
of COX-1 and COX-2
Lower toxicity and
better acceptance in
some patients
Headache, patent ductus
arteriosis, tinnitus,
dizziness, prolong
bleeding time
Fever, pain, anti-
inflammatory, anti-
platelet, osteoarthritis,
rheumatoid arthritis
Fenoprofen
Flurbiprofen
Ketoprofen
Naproxen Naproxen is
considered by some
experts as one of the
safest NSAID
Oxaprozin Long half-life permit
once daily dosing
Oxicams
Piroxicam Inhibits both COX-1
and COX-2, with
preferential binding
for COX-2
Long half-life permit
once or twice daily
dosing
GI disturbance in 20%
patients
osteoarthritis, rheumatoid
arthritis, ankylosing
spondylitis
Meloxicam Long half-life permit
once or twice daily
dosing
Less GI irritation than
Piroxicam
Fenamates
Mefenamic
acid
Diarrhoea, inflammation
of bowel, haemolytic
anaemia
Meclofenamic
acid
COX-2 inhibitors
Celecoxib More selectively
inhibit COX-2
Less GI irritation than
aspirin
Potential for increasing
myocardial infarctions
RA, rheumatoid arthritis,
acute to moderate pain
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methods, and by activating the pain inhibitory mechanisms, one can reduce pain and improve
the quality of life of patient with chronic pain.
3.4. Psychological therapies
Psychological factors have a big influence on the perception of pain, as well as the effectiveness
of the treatment. Therefore, all patients with chronic pain should be able to take advantage of
professional psychological help, which can affect the emotional aspect of pain. Among the
psychological methods that can be effective as a technique supporting the treatment of chronic
pain, the most commonly used are cognitive therapy, behavioural therapy, relaxation tech-
niques and hypnotherapy.
3.5. Invasive methods
These procedures of pain management should be executed and administered by experienced
specialists in specific cases. Numbers of methods are available, i.e. individual nerves block, intra-
thecal administration of drugs (e.g. epidural anaesthesia during childbirth) to neurodestructive
NSAID Mechanism of action Therapeutic
advantages
Therapeutic
disadvantages
Indications
and strokes, headache,
diarrhoea
Heteroaryl acetic acids
Diclofenac Selective COX-2
inhibitor
Employed in long-
term therapy
osteoarthritis, rheumatoid
arthritis, ankylosing
spondylitis
Tolmetin Anti-inflammatory, anti-
pyretic, analgesic
Ketorolac Fatal peptic ulcer, GI
Bleeding, Perforation of
the stomach or intestine
Moderate to Severe pain,
moderate inflammation,
allergic conjunctivitis
Source: Clark et al. [43].
Table 4. Classification of currently used Non-steroidal anti-inflammatory drugs along with mechanism and indications.
Scientific name/common name Family Parts used Medicinal used References
Berberis calliobotrys Berberidaceae Stem Analgesic for Rheumatoid
arthritis
[44, 45]
Manilkara zapota Sapotaceae Leaves Analgesic [46]
Clerodendrum phlomidis Verbenaceae Stem bark Analgesic [47]
Bach Araceae Rhizome Analgesic [48]
Ocimum suave Lamiaceae Analgesic [48]
Lippia adoensis Verbenaceae flower Analgesic [48]
Ajuga remota /bugle Lamiaceae Analgesic [48]
Pimpinella anisum Umbellifera Seeds Narcotic analgesic [49]
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procedures (neurolysis, thermo lesion,) and neurosurgery. Advance medicine provides many
different methods for the management of pain.
4. Plant sources of analgesics
Due to obvious adverse effect of synthetic drugs, herbal medicinal plants are focusing to
develop newer analgesic agents with fewer side effects. Some plants having analgesic activity
are given in Table 5.
5. Experimental models for screening of analgesic substances
The animal models employed for screening of analgesic agents include
5.1. Pain-state models using thermal stimuli
For the activation of cutaneous receptors, heat is a suitable stimulus. Nociceptive stimulation
origin can be far apart from its target, for example radiant heat from a lamp in a direct touch
Scientific name/common name Family Parts used Medicinal used References
Myrtus communis Myrtaceae Leaves Narcotic analgesic [50]
Tribulus terrestris Zygophyllaceae Aerial Narcotic analgesic [51]
Sinapis arvensis Solanaceae Aerial Narcotic analgesic [51]
Withania somnifera Solanaceae Leaves and
fruit
Narcotic analgesic [51]
Peganum harmala Zygophyllaceae Whole plant Narcotic analgesic [51]
Hibiscus rosa sinensis Malvaceae leaves Analgesic [52]
Stylosanthes fruticosa Papilionaceae Whole plant Analgesic [53]
Polyalthia longifolia Annonaceae Leaves Analgesic [53]
Ficus glomerata Moraceae Bark and leaves Toothache, analgesic [53]
Baugainvillea spectabilis Nyctaginaceae Leaves Analgesic [53]
Toona ciliata Meliaceae heart wood Analgesic [53]
Sida acuta Malvaceae whole plant Analgesic [53]
Chococca brachiata Rubiaceae Root Anti-inflammatory, analgesics [54]
Bauhinia racemosa Caesalpiniaceae Stem bark Analgesic [54]
Casearia sylvestris Swartz. (wild
coffee)
Flacurtiaceae Leaves and
bark
Anti-inflammatory, analgesics [54]
Elephantopus scaber Elephantopus
scaber
Leaves Anti-inflammatory, analgesics [54]
Table 5. Some plant sources under study to develop new analgesics.
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with the skin. Comparatively, radiant heat comprises a selective stimulus for nociceptors;
moreover, it has an advantage of producing no tactile stimulus over the other ways of thermal
stimulation.
5.1.1. The tail-flick model using radiant heat/immersion of the tail in hot water
It is one of the most simplified procedures used in human subjects with radiant heat [55]. In
fact, Hardy et al. finally used this method in rats [56]. After the exposure to thermal radiation
of the tail of an animal it takes out the tail by a brief dynamic movement [57]. This separation
of the tail from the heat source is termed as ‘tail-flick latency’. In this method, a timer is started
at the time of application of heat and the time taken for the rat to withdraw its tail from heat
source is recorded. Withdrawal time is usually within 2–10 s. It is advisable to not to lengthen
the exposure to radiant heat more than 20 s as the skin of the tail may be burnt. In order to
control the intensity of the current passing through the filament, a rheostat is inserted in the
apparatus which further controls the intensity of radiant heat. Some investigators have used
cold as a substitute of hot stimuli; this test can be used on monkeys as well. The use of
immersion of the tail is apparently a variant of the test described above [58].
5.1.2. Paw-withdrawal test
This test is completely comparable to the test of D’Amour and Smith [59] but have the benefit
that it does not involve the pre-eminent organ of thermoregulation in rats and mice, i.e. the
tail [60]. In this test, a paw is exposed to radiant heat that had previously been swollen by a
subcutaneous injection of carrageenan. By exposure to ultraviolet rays, inflammation can also
be produced. Heat applied to a freely moving animal is an advantage of these types of
tests [61].
5.1.3. Hot-plate model
In this test, a mouse or rat is presented into an open-ended cylindrical space with a floor
composed of metallic plate that is heated by boiling liquid or a thermoderm [62]. Two
behavioural components are produced by heating the plate at constant temperature that is
calculated in terms of their reaction times, namely jumping and paw licking. In terms of
analgesic chemicals, the paw licking behaviour is influenced only by opioids. On the con-
trary, by using less powerful analgesics, for example, paracetamol or acetylsalicylic acid, the
jumping reaction time can be increased, especially when the temperature of the plate is 50C
or less or if the temperature is changing incrementally and in linear fashion, e.g. from 43 to
52C at 2.5C/min [63]. The behaviour is more complex in the rat and relatively stereotyped
in the mouse like it sniffs, licks its forepaws, licks its hind paws, straightens up, and stamps
its feet, starts and stops washing itself, among other things. These behaviours have been
labelled ‘chaotic defensive movements’ [64].
5.1.4. Pain-state models using cold stimuli
For stimulation and measurement of pain in mice, a new animal model has been developed
and designed. This laboratory model (M-model) basically consists of four parts (i) perspex-box,
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(ii) M-Zone, (iii) ice-tray and (iv) ice floor. At the start, the mouse is exposed to different parts
of the M-model mainly M-Zone for about 60 s, so that the mouse is sensitive of the existence of
M-Zone prior to the initiation of the experiment. From the top/ceiling of the perspex box, the
animal is inserted. The ice tray containing of ice block is slide onto the floor of the perspex box.
When the animal is not able to bear the cold surface of ice floor, it escapes to M-Zone. The time
taken by the animal to run away into the M-Zone (Flight-Zone) when placed on the ice-floor is
called endurance time. This time is recorded with the help of a stopwatch. In general, mice take
about 4–6 s to escape into the M-Zone to evade ice floor. Separate groups of animals are pre-
treated with narcotics such as butorphanol (partial opioid agonist, 2 mg/kg, s. c), tramadol
(opioid agonist, 5 mg/kg, s. c), pentazocine (10 mg/kg, s. c) and non-narcotic analgesics such as
ketoprofen (non-selective COX inhibitor, 5 mg/kg, p. o), diclofenac (non-selective COX inhibi-
tor, 15 mg/kg, i. p) and meloxicam (preferential COX-2 inhibitor, 5 mg/kg, s. c) to determine
their effect on endurance time. This time is recorded at 0, 15, 30, 45, 60, 120 and 180 min after
administration of the standard drugs [65].
5.2. Pain-state models using mechanical stimuli
5.2.1. Strain gauges
In this test, an increasing amount of pressure is applied to a punctiform area on the hind paw
or, far less frequently, on the tail. The tail or paw is wedged between a plane surface and a
blunt point mounted on top of a system of cog wheels with a cursor that can be moved in the
direction of length of a graduated beam [66]. When the pressure increases, following step wise
reactions occurs, i.e. the reflex removal of the paw or a complex movement of the animal to free
its captured limb and at last a vocal response is noticed. Randall and Selitto with the aim of
enhancing the sensitivity of the test offer comparison of thresholds seen with an inflamed paw
and with a healthy paw [67].
5.2.2. von-Frey filaments
The key method for the study of pain in animal models is the assessment of mechanosen-
sitivity. This is frequently executed with the use of von-Frey filaments in an up-down testing
model. This is the most commonly used method for measuring pain in animals described by
Vivancos [68] for mechanosensitivity testing in rodents. Though, in this method, animals are
getting a changeable amount of stimuli which may direct the animals in distinctive groups
getting diverse testing experiences that affect their subsequent responses. In order to standard-
ize the measurement of mechano-sensitivity, a simplified up-down method (SUDO) for reck-
oning paw withdrawal threshold (PWT) with von-Frey filaments has been developed that uses
a constant number of five stimuli per test [69].
5.3. Pain-state models using electrical stimuli
5.3.1. Electrical stimulation of the tail
Progressively escalating strength of electrical stimuli can be applied in range (lasting for some
milliseconds) through subcutaneous electrodes positioned in the tail of the mouse or the rat.
One can see the following: when such slowly increasing intensities of electrical stimuli are
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applied from invariable voltages 40–50 V, i.e., the impulse movement of the tail, vocalization
occurs at the time of stimulation, and then, utterance continuing ahead for the period of
stimulation. Due to the electrical current, the animal may be died. Morphine or morphine-like
drugs are useful in this model [70].
5.3.2. Grid-shock test
Approximately weighing of 18–20 g of male mice is put into the clear plastic chambers. The
floor of box spaced about 1 mm apart is wired firmly with stainless steel wire. In the form of
square wave pulses, the stimulus is given 30 cycles/s with a period of 2 ms/pulse. By escalating
shock intensities, the mice gasp, show a frightening reaction, increase movement or effort to
jump. Pain threshold response is defined as the behaviour correctly reflected on the oscillo-
scope by marked vacillation of the displayed pulse. Prior to administration of the test drug the
pain thresholds are find out in each individual mouse twice at 15, 30, 60, 90 and 120 min
subsequent dosing [71].
5.3.3. Stimulation of the tooth pulp
In this method, electric current is applied to stimulate the tooth-pulp of the animal. Pain
symbol is exhibited as biting, chewing, licking and head flicking.
Rabbits of either sex are used as animal model. Thiopental 15 mg/kg or fentanyl-citrate 0.2 mg/kg
i.v. produces anaesthesia. A high-speed dental drill is used to create pulp chambers in the lateral
margins of the two front upper incisors.
Rectangular current with a frequency of 50 Hz for 1 s is applied. The 0.2-mA electrical current
produces the phenomenon of licking [72].
5.3.4. Monkey-shock titration test
This model carries monkeys as animal model and kept them in restraining chairs. The monkey
shock titration is a final evaluation of a new compound before administration to man. Electrical
current is conveyed by a Coulbourn Instrument programmable stunner through cathodes
coupled to two test tube clasps, which are connected to a shaved bit of the tail. The current
ranges from 0 to 4mA through 29 progressive steps. This current is suppressed by a bar pressed
by monkey. On the day before the drug administration, a stable baseline shock level is recog-
nized for each monkey. Drugs in different doses like 3.0 mg/kg i.m. morphine, 1.7 mg/kg i.m.
methadone, and10mg/kg i.m. pentazocinewereused.However, this test is time consuming [73].
5.3.5. Stimulation of the limbs
For pharmacological studies of analgesia, electromyographic recordings of nociceptive limb
reflexes have been used for, but they are far less common than behavioural tests. These
electromyographic studies have permitted the measurement of reactions paying little heed to
whether there is any development.
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5.4. Pain-state models using chemical stimuli
The experimental models in which chemical stimulation is done with the administration of
algogenic agents represent an irreversible, slow, and progressive form of stimulation, which
are nearby in nature to clinical pain.
5.4.1. Formalin test
The formalin test in rats, a chronic pain model is used to assess the centrally active analgesic
agents. In this test, excessive licking and biting of the paw is recorded as response after the
administration of formalin (37% solution of formaldehyde) into the front paw. Both paws
resting on the floor indicated the analgesic response or protection of the test drug. The
response as painful behaviour can be evaluated on a four-level scale related to posture:
0 represents normal texture; 1 represents the injected paw not supporting the animal but
leftovers on the ground; 2 represents animal raised up the injected paw visibly; and 3 repre-
sents animal shows responses like licking, nibbling or shaking of injured paw [74].
5.4.2. Acetic acid induced writhing test
In this method, pain is indicated as a characteristic behaviour of contraction of abdominal
muscles and stretching of hind paws along with twisting of dorso-abdominal muscles, andmotor
in co-ordination in rats or mice (called writhing) after the administration of allogenic agents like
phenyl quinone or acetic acid into the peritoneal cavity which irritate the serous membrane;
therefore, this test is called ‘writhing test’. These writhings are counted as per unit of time [74].
5.4.3. Stimulation of hollow organs
In hollow organs such as rat colon, formalin is injected, and a complex biphasic type of ‘true
visceral pain’ is exhibited in two phases. In first phase, contraction and stretching of body and in
second phase, abdominal licking and nibbling behaviour is shown by the animal. Intravesical
administration of capsaicin or turpentine produce bladder pain, glycerol produces abdominal
constrictions and intrauterine injections of mustard oil show complex behaviour patterns in a
number of models including rats. Another mean of stimulus for colorectal distension in rat is an
inflatable balloon [75, 76].
6. Conclusion
The ASIC family is a potential target for new analgesics. In rheumatoid arthritis and vascular
ischemia, as well as in the routine perioperative settings, inflammation and ischemic pain
conditions are a sign mark of acidic nociception which can be reduce by the NSAIDs and by
direct inhibition of sensory neuron ASIC current [77].
Work is currently in progress on a more selective and potent ASIC blocker and could poten-
tially be an effective agent in the treatment of inflammatory and ischemic acute or chronic pain
in the future [78]. Key regulators of membrane excitability are inflammatory mediators and
key receptors (kinins, mPGEs), ion channels (TRPV1, NaV 1.7), and neurotrophins (NGF).
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Similarly, α(2A)-adrenoceptor agonists also proven to be effective in various pain conditions,
in the spinal dorsal horn, by inhibitory action on α(2A)-adrenoceptors on central terminals of
primary afferent nociceptors (presynaptic inhibition), by direct α2-adrenergic action on spinal
pain-relay neurons (post-synaptic inhibition) noradrenaline released from descending path-
ways originating in the pontine A5–A7 cell groups decreases pain and by α1-adrenergic
activation of inhibitory interneurons. Furthermore, α(2C)-adrenoceptors on axon terminals of
excitatory interneurons might subsidize to spinal control of pain [79]. These targets are cur-
rently under work to establish new analgesics with minimum side effects as exhibited by the
currently used COX inhibitors.
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